Mexican newspaper estimates promising Cuban drug against Alzheimer's disease

Mexico City, March 24 (RHC)-- Mexico's La Jornada newspaper describes the neuroprotective drug NeuralCIM for nasal administration for Alzheimer's patients developed in Cuba as hope from science.

In a report dated from Havana, the newspaper notes that the clinical trials conducted in phases II and III with the drug during 48 weeks showed that it is safe and well-tolerated, with no serious adverse events.

La Jornada quotes Teresita Rodriguez, manager of the project. She said that a considerable part of the patients showed a reduction in the progression of cognitive deterioration and improvement of secondary variables.

She added that two clinical trials are now planned: one in Havana, comparative, and the other in the rest of the provinces in phase IV. In all cases, she added, the participants will receive Alzheimer's drugs.

On March 8, the Center for State Control of Medicines, Equipment, and Medical Devices of the island approved the Conditional Health Registration of the drug NeuroEpo in the indication of mild and moderate Alzheimer's disease.

According to the document issued by the Center, the registration for NeuralCim (trade name of NeuroEpo) was approved after evaluating the documentation submitted by the CIM. It will be valid for three years from the date of issuance of the registration certificate.

The description of the drug indicates that it is a nasal formulation of recombinant human erythropoietin (EPO) with a low content of sialic acid, an isoform with a composition similar to that produced in the central nervous system.